SITE015-0044

SITE015 (POL) › SITE015-0044

SITE015-0044

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2025-10-22

enrolled

AEs

3

Serious

0

Dropout signal

–

Adverse events

3

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-10-30 (study day 183); relationship: RELATED

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-05-15 (study day 15); relationship: not assessed

moderate assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-05-15 (study day 15); relationship: RELATED

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.